TOLREMO has created ground-breaking scientific knowledge that allows it to pursue its passion to discover and develop novel targeted therapeutics that will meaningfully extend the lives of patients suffering from cancer.

TOLREMO therapeutics AG (“TOLREMO”) is a privately held research-stage biotechnology company. TOLREMO was founded in March 2017 as an ETH Spin-off by Dr. Stefanie Flückiger-Mangual, Prof. Dr. Wilhelm Krek, Prof. Dr. Karl-Heinz Altmann, Dr. Isaac Kobrin, and Emmanuel Savioz (MBA). The company engages in the discovery and development of small molecule drugs that target novel drug resistance pathways in cancer therapy. Despite medical advances, resistance to cancer therapies continues to limit the long-term survival of many cancer patients. TOLREMO’s vision is to meaningfully prolong the lives of cancer patients using its personalized anti-drug resistance therapies.

TOLREMO is headquartered on the ETH Hönggerberg campus in Zurich, Switzerland, where the company is part of a dynamic scientific and entrepreneurial community composed of world-leading academic research laboratories, flourishing life sciences spin-offs and cutting-edge technology platforms. TOLREMO enjoys broad access to state-of-the art ETH infrastructure including laboratory space and an industry standard robotic screening facility.